Article Text
Abstract
Objectives Fulminant viral hepatitis (FH) remains a serious clinical problem for which the underlying pathogenesis remains unclear. The B and T lymphocyte attenuator (BTLA) is an immunoglobulin-domain-containing protein that has the capacity to maintain peripheral tolerance and limit immunopathological damage during immune responses. However, its precise role in FH has yet to be investigated.
Design BTLA-deficient (BTLA−/−) mice and their wild-type littermates were infected with murine hepatitis virus strain-3 (MHV-3), and the levels of tissue damage, cell apoptosis, serum liver enzymes, fibrinogen-like protein 2 (FGL2) and cytokine production were measured and compared. Survival rate was studied after MHV-3 infection with or without adoptive transferring macrophages.
Results FGL2 production, liver and spleen damage, and mortality were significantly reduced in BTLA−/− mice infected with MHV-3. This effect is due to rapid, TRAIL (TNF-related apoptosis-inducing ligand)-dependent apoptosis of MHV-3-infected macrophages in BTLA−/− mice. The early loss of macrophages resulted in reduced pathogenic tumour necrosis factor α (TNFα) and FGL2 levels and lower viral titres. The importance of TNFα in MHV-3-induced pathology was demonstrated by increased mortality in TNFα-treated MHV-3-infected BTLA−/− mice, whereas TNFα−/− mice were resistant to the infection. Moreover, adoptively transferring macrophages to BTLA−/− mice caused sensitisation, whereas blocking BTLA protected wild-type mice from virus-induced FH mortality.
Conclusions BTLA promotes the pathogenesis of virus-induced FH by enhancing macrophage viability and function. Targeting BTLA may be a novel strategy for the treatment of FH.
- BTLA
- Fulminant viral hepatitis
- FGL2
- TNFα
- immune
- acute liver failure
- hepatobiliary pathology
- infectious disease
- inflammation
- immune-mediated liver damage
- immunology in hepatology
- vitamins
- immunology
- inflammatory mechanisms
- cell biology
- cellular immunity
- cellular immunology